OA
UTHR icon

Oxbow Advisors’s United Therapeutics UTHR Stock Holding History

Oxbow Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-16,930
Closed -$2.43M – 277
2016
Q4 		$2.43M Sell
16,930
-625
-4% -$79.8K 0.3% 86
2016
Q3 		$2.07M Sell
17,555
-415
-2% -$49.9K 0.28% 97
2016
Q2 		$1.91M Sell
17,970
-17,425
-49% -$1.94M 0.27% 102
2016
Q1 		$3.94M Buy
35,395
+17,000
+92% +$2.15M 0.56% 52
2015
Q4 		$2.88M Sell
18,395
-400
-2% -$58.2K 0.36% 88
2015
Q3 		$2.47M Buy
18,795
+1,750
+10% +$281K 0.41% 79
2015
Q2 		$2.96M Buy
+17,045
New +$3.07M 0.38% 77

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oxbow Advisors's UTHR Position: Q1 2017 in Review

Oxbow Advisors sold out of United Therapeutics (UTHR) in Q1 2017, closing a stake of 16,930 shares — an estimated $2.43M sold.

Oxbow Advisors first reported a position in UTHR in Q2 2015 and held it in 7 quarters. The position peaked at $3.94M in Q1 2016. 411 funds tracked by Wall St. Rank hold UTHR as of Q1 2017.

  • Oxbow Advisors reported no remaining United Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Oxbow Advisors sold 16,930 United Therapeutics shares in Q1 2017, an estimated $2.43M.
  • Oxbow Advisors first reported a position in United Therapeutics in Q2 2015 and held it in 7 quarters.
  • Oxbow Advisors's United Therapeutics position peaked at $3.94M in Q1 2016.
  • 411 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2017.

Based on Oxbow Advisors's 13F filing for Q1 2017, filed 28 Apr 2017.